A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Merck Sharp & Dohme LLC
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
SCRI Development Innovations, LLC
Pfizer
Roswell Park Cancer Institute
Baylor Research Institute
Institut du Cancer de Montpellier - Val d'Aurelle
Gruppo Oncologico del Nord-Ovest
UNICANCER
City of Hope Medical Center
NuCana plc
Institut Bergonié
IFOM ETS - The AIRC Institute of Molecular Oncology
Memorial Sloan Kettering Cancer Center
Pfizer
City of Hope Medical Center
Baylor College of Medicine
UNC Lineberger Comprehensive Cancer Center
NRG Oncology
Charite University, Berlin, Germany
Memorial Sloan Kettering Cancer Center
Sun Yat-sen University
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Ohio State University Comprehensive Cancer Center
Peking Union Medical College Hospital
Fudan University
Fudan University
Medical University of Vienna
NSABP Foundation Inc
Asan Medical Center
Wake Forest University Health Sciences
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Barbara Ann Karmanos Cancer Institute
Institut Bergonié
Tanta University
Alliance for Clinical Trials in Oncology
SCRI Development Innovations, LLC
Medical Research Council
Medical Research Council
University of Louisville
China Medical University, China